Dr. William Sandborn, Professor of Medicine and Chief, Division of Gastroenterology and Director, University of California San Diego Inflammatory Bowel Disease Center, believes the use of two co-primary endpoints for Crohn’s disease trials is raising the bar for new treatment options.

Dr. William Sandborn

Dr. William Sandborn, Professor of Medicine and Chief, Division of Gastroenterology and Director, University of California San Diego Inflammatory Bowel Disease Center, believes the use of two co-primary endpoints for Crohn’s disease trials is raising the bar for new treatment options.